Back

Spatially-resolved single cell atlas of liposarcoma reveals lineage hierarchies, immune niches, and regulatory circuits

Denu, R. A.; Kochat, V.; Zheng, Z.; Satpati, S.; Truong, D. D.; Arslan, E.; Weistuch, C.; Divenko, M.; Wu, M.; Padron, W.; Ingram, D. R.; Wani, K. M.; Wang, W.-L.; Landers, S. M.; Beird, H. C.; McCuiston, J. L.; Simmons, A.; Albertorio-Saez, L. M.; Maryanski, D. N.; Szany, C. C.; Venters, B. J.; Windham, C. L.; Keogh, M.-C.; Torres, K. E.; Roland, C. L.; Keung, E. Z.; Nassif Haddad, E. F.; Lazar, A. J.; Ludwig, J. A.; Somaiah, N.; Rai, K.

2026-03-25 cancer biology
10.64898/2026.03.23.713651 bioRxiv
Show abstract

Well-differentiated and dedifferentiated liposarcoma (WDLPS and DDLPS) exhibit markedly different clinical behaviors, with DDLPS showing greater aggressiveness, higher recurrence and metastasis rates, and worse outcomes. Using single-nucleus multiome sequencing, epigenomic profiling, and spatial transcriptomics, we characterized cellular and epigenetic heterogeneity between these subtypes at single-cell and spatial resolution. We found distinct phenotypic states reflecting altered lineage differentiation and plasticity: DDLPS is dominated by early-differentiated progenitor-like cells, sclerotic WDLPS displays broader mesenchymal lineage plasticity, and adipocytic WDLPS contains abundant committed adipocytes. The DDLPS immune microenvironment was dominated by immunosuppressive macrophages, whereas WDLPS harbored more T cells and inflammatory macrophages. Notably, sclerotic WDLPS displayed intermediate cellular and molecular features, suggesting it may represent a distinct WDLPS subtype. Importantly, we identified novel gene regulatory circuits underlying each state, including FABP4/PPARG programs in adipocytic WDLPS, GLI2/TCF7L2/RBPJ/KLF7 programs in sclerotic WDLPS, and KLF7/FOSL2/SP3/GLI2/RBPJ programs in DDLPS. H3K27ac-marked enhancers were enriched near adipocytic marker genes in WDLPS and mesenchymal markers in DDLPS. Together, these findings reveal the cellular heterogeneity of tumor and immune compartments across liposarcoma subtypes and identify regulatory programs driving their differentiation states. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=155 SRC="FIGDIR/small/713651v1_ufig1.gif" ALT="Figure 1"> View larger version (73K): org.highwire.dtl.DTLVardef@1c84ee1org.highwire.dtl.DTLVardef@1b2ad42org.highwire.dtl.DTLVardef@18ce5a6org.highwire.dtl.DTLVardef@138f615_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Cell Reports
1338 papers in training set
Top 0.1%
22.4%
2
Nature Communications
4913 papers in training set
Top 10%
14.7%
3
Cancer Research
116 papers in training set
Top 0.1%
9.1%
4
Cancer Cell
38 papers in training set
Top 0.2%
4.8%
50% of probability mass above
5
Cancer Discovery
61 papers in training set
Top 0.4%
4.3%
6
Cell Reports Medicine
140 papers in training set
Top 1%
3.6%
7
Clinical Cancer Research
58 papers in training set
Top 0.5%
3.6%
8
eLife
5422 papers in training set
Top 32%
2.6%
9
Cell Genomics
162 papers in training set
Top 2%
2.1%
10
Science Advances
1098 papers in training set
Top 17%
1.7%
11
Genome Medicine
154 papers in training set
Top 5%
1.7%
12
Developmental Cell
168 papers in training set
Top 9%
1.5%
13
Nature Cancer
35 papers in training set
Top 1.0%
1.2%
14
Communications Biology
886 papers in training set
Top 17%
0.9%
15
JCI Insight
241 papers in training set
Top 6%
0.9%
16
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
17
Cell Systems
167 papers in training set
Top 10%
0.9%
18
Nature Cell Biology
99 papers in training set
Top 4%
0.9%
19
Nature
575 papers in training set
Top 14%
0.9%
20
Molecular Cancer Research
42 papers in training set
Top 0.7%
0.8%
21
Cancers
200 papers in training set
Top 4%
0.8%
22
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 44%
0.7%
23
Neuro-Oncology
30 papers in training set
Top 0.7%
0.7%
24
Cancer Immunology Research
34 papers in training set
Top 0.5%
0.7%
25
Cell
370 papers in training set
Top 18%
0.7%
26
npj Precision Oncology
48 papers in training set
Top 1%
0.7%
27
Cell Stem Cell
57 papers in training set
Top 2%
0.7%
28
Breast Cancer Research
32 papers in training set
Top 0.6%
0.6%